COVID-19 Vaccination in Inflammatory Bowel Disease (IBD)
Open Access
- 9 May 2022
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (9) , 2676
Abstract
Vaccines against SARS-CoV-2 are believed to play a key role in the suppression of the COVID-19 pandemic. However, patients suffering from inflammatory bowel diseases (IBD) were excluded from SARS-CoV-2 vaccines trials. Therefore, concerns regarding vaccination efficacy and safety among those patients were raised. Overall, vaccination is well tolerated in the IBD population, and different gastroenterological societies recommend vaccinating patients with IBD at the earliest opportunity to do so. Nevertheless, very little is known about the safety of COVID-19 vaccines in special IBD populations such as pregnant and breastfeeding women or pediatric patients, and further research on this matter is crucial. The available data on vaccine efficacy are promising and show high seroconversion rates in IBD patients on different immune-modifying therapies. However, patients treated with high doses of systemic corticosteroids, infliximab or infliximab and immunomodulators may have a blunted response to the vaccination. The data on COVID-19 vaccination willingness among patients with IBD are conflicting. Nevertheless, vaccine effectiveness and safety are reported to be the most common reasons for hesitancy. This review examines the effectiveness and safety of COVID-19 vaccines and describes vaccination willingness and the reasons for potential hesitancy among patients with IBD.Keywords
Funding Information
- Uniwersytet Medyczny w Lodzi (503/1-002-01/503-11-001-19-00)
This publication has 57 references indexed in Scilit:
- Review article: prevention, diagnosis and management of COVID‐19 in the IBD patientAlimentary Pharmacology & Therapeutics, 2020
- British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemicGut, 2020
- Vaccination in Patients with Inflammatory Bowel DiseasesDigestion, 2020
- British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adultsGut, 2019
- Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab TherapyInflammatory Bowel Diseases, 2018
- Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab TherapyInflammatory Bowel Diseases, 2016
- Vaccination in Inflammatory Bowel Disease Patients: Attitudes, Knowledge, and UptakeJournal of Crohn's and Colitis, 2015
- Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel diseaseJournal of Crohn's and Colitis, 2014
- Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial resultsGut, 2014
- Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study*Inflammatory Bowel Diseases, 2012